Prognostic factors for survival after isolated limb perfusion for malignant melanoma

European Journal of Surgical Oncology

Volumn 29, Issue 10, 2003, Pages 916-921

  Noorda, E M ^a   Vrouenraets, B C ^a   Nieweg, O E ^a   van Geel, A N ^b   Eggermont, A M M ^b   Kroon, B B R ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Melanoma; Regional perfusion; Risk factors; Survival

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANKYLOSIS; ARTICLE; BLISTER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FIBROSIS; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; INOPERABLE CANCER; LIMB PERFUSION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NERVE COMPRESSION; NERVE INJURY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION;

EID: 0345170029     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2003.09.002     Document Type: Article

References (17)

1. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996; 83: 1319-28.
2. Eggermont AM, Schraffordt Koops H, Liénard D, Kroon BB, van Geel AN, Hoekstra HJ et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-65.
3. Liénard D, Eggermont A, Schraffordt Koops H, Kroon BBR, Towse G, Hiemstra S et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.
4. Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
5. Krementz ET, Sutherland CM, Muchmore JH. Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am 1996; 76: 1313-30.
6. Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551-61.
7. Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001; 8: 771-8.
8. Klaase JM, Kroon B, van Geel AN, van Wijk J, Franklin HR, Eggermont A et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994; 178: 564-72.
9. Kroon B, Klaase J, van Geel A, Eggermont A, Franklin H, van Dongen J. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993; 29A: 325-8.
10. Kroon B, Klaase J, van de Merwe SA, van Dongen J, van der Zee J. Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: a pilot study. Reg Cancer Treatment 1992;: 305-8.
11. Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-10.
12. WHO Handbook for Reporting Results of Cancer Treatment Geneva: WHO; 1979.
13. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioural Sciences. Hillsdale, NJ: LEA Publishers, 1975.
14. Overgaard J, Gonzalez GD, Hulshof MC, Arcangeli G, Dahl O, Mella O et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European society for hyperthermic oncology. Lancet 1995; 345: 540-3.
15. Strobbe LJ, Nieweg OE, Kroon BB. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 1997; 23: 435-8.
16. Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, Hart AA. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115: 39-45.
17. Fraker D, Alexander H, Ross M, Bartlett D, Tyler D, Libutti LS et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Ann Surg Oncol 2002; (Supplement): S8.